Novel use of surveillance data to detect HIV-infected persons with sustained high viral load and durable virologic suppression in New York City

PLoS ONE

Volumn 7, Issue 1, 2012, Pages

  Terzian, Arpi S ^a   Bodach, Sara D ^a   Wiewel, Ellen W ^a   Sepkowitz, Kent ^b   Bernard, Marie Antoinette ^a   Braunstein, Sarah L ^a   Shepard, Colin W ^a  

^a NEW YORK CITY DEPARTMENT OF HEALTH AND MENTAL HYGIENE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGE; ARTICLE; COHORT ANALYSIS; DISEASE ASSOCIATION; DISEASE REGISTRY; DISEASE SURVEILLANCE; DISEASE TRANSMISSION; DRUG ABUSE; DURABLY SUPPRESSED VIRAL LOAD; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFORMATION PROCESSING; LIFESPAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEGRO; PATIENT MONITORING; RETROSPECTIVE STUDY; SUSTAINED HIGH VIRAL LOAD; TREATMENT OUTCOME; UNITED STATES; VIRUS LOAD; CD4 LYMPHOCYTE COUNT; FACTUAL DATABASE; HEALTH SURVEY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; LONGITUDINAL STUDY; METHODOLOGY; PHYSIOLOGY; STATISTICS; UTILIZATION REVIEW; VIROLOGY;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DATABASES, FACTUAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LONGITUDINAL STUDIES; MALE; NEW YORK CITY; POPULATION SURVEILLANCE; RETROSPECTIVE STUDIES; VIRAL LOAD;

EID: 84856167129     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0029679     Document Type: Article

References (47)

1. Mellors JW, Munoz A, Giorgi JV, Margolick JB, Tassoni CJ, et al. (1997) Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 126: 946-954.
2. Sterling TR, Vlahov D, Astemborski J, Hoover DR, Margolick JB, et al. (2001) Initial plasma HIV-1 RNA levels and progression to AIDS in women and men. N Engl J Med 344: 720-725.
3. Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK, (2002) Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Ann Intern Med 137: 381-433.
4. Attia S, Egger M, Muller M, Zwahlen M, Low N, (2009) Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS 23: 1397-1404.
5. Lohse N, Kronborg G, Gerstoft J, Larsen CS, Pedersen G, et al. (2006) Virological control during the first 6-18 months after initiating highly active antiretroviral therapy as a predictor for outcome in HIV-infected patients: a Danish, population-based, 6-year follow-up study. Clin Infect Dis 42: 136-144.
6. Viard JP, Burgard M, Hubert JB, Aaron L, Rabian C, et al. (2004) Impact of 5 years of maximally successful highly active antiretroviral therapy on CD4 cell count and HIV-1 DNA level. AIDS 18: 45-49.
7. Donnell D, Baeten JM, Kiarie J, Thomas KK, Stevens W, et al. (2010) Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet 375: 2092-2098.
8. Althoff KN, Gange SJ, Klein MB, Brooks JT, Hogg RS, et al. (2010) Late presentation for human immunodeficiency virus care in the United States and Canada. Clin Infect Dis 50: 1512-1520.
9. Torian LV, Wiewel EW, (2011) Continuity of HIV-related medical care, New York City, 2005-2009: Do patients who initiate care stay in care? AIDS Patient Care STDS 25: 79-88.
10. Torian LV, Wiewel EW, Liu KL, Sackoff JE, Frieden TR, (2008) Risk factors for delayed initiation of medical care after diagnosis of human immunodeficiency virus. Arch Intern Med 168: 1181-1187.
11. Academies. BophaphpIoMotN, editor (2003) Measuring what matters: Allocation, planning, and quality assessment for the Ryan White CARE Act:. The National Academies Press.
12. (2010) TLC-plus: A study to evaluate the feasibility of an ehanced test, link to care, plus treat approach for HIV prevention in the United States. HIV Prevention Trials Network.
13. (2010) National HIV/AIDS Strategy. Office of National AIDS Policy.
14. Das M, Chu PL, Santos GM, Scheer S, Vittinghoff E, et al. (2010) Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco. PLoS One 5: e11068.
15. Montaner JS, Wood E, Kerr T, Lima V, Barrios R, et al. (2010) Expanded highly active antiretroviral therapy coverage among HIV-positive drug users to improve individual and public health outcomes. J Acquir Immune Defic Syndr 55 (Suppl 1): S5-9.
16. (1999) Guidelines for national human immunodeficiency virus case surveillance, including monitoring for human immunodeficiency virus infection and acquired immunodeficiency syndrome. Centers for Disease Control and Prevention. MMWR Recomm Rep 48: 1-27, 29-31.
17. Public Health Law Article 21York SoN, editor (1983) Public Health Law Article 27-F- HIV and AIDS Information; Public Health Law Article 21, Title III-HIV Reporting and Partner Notification (1998); Code of Administrative Rules and Regulations, Title 10 Part 63 (2000).
18. Lee LM, McKenna MT, Janssen RS, (2003) Classification of transmission risk in the national HIV/AIDS surveillance system. Public Health Rep 118: 400-407.
19. Zeger SL, Liang KY, (1986) Longitudinal data analysis for discrete and continuous outcomes. Biometrics 42: 121-130.
20. Degenhardt L, Mathers B, Vickerman P, Rhodes T, Latkin C, et al. Prevention of HIV infection for people who inject drugs: why individual, structural, and combination approaches are needed. Lancet 376: 285-301.
21. Wolfe D, Cohen J, (2010) Human rights and HIV prevention, treatment, and care for people who inject drugs: key principles and research needs. J Acquir Immune Defic Syndr 55 (Suppl 1): S56-62.
22. Jenness SM, Neaigus A, Hagan H, Wendel T, Gelpi-Acosta C, et al. (2010) Reconsidering the internet as an HIV/STD risk for men who have sex with men. AIDS Behav 14: 1353-1361.
23. Strathdee SA, Hallett TB, Bobrova N, Rhodes T, Booth R, et al. (2010) HIV and risk environment for injecting drug users: the past, present, and future. Lancet 376: 268-284.
24. Jenness SM, Hagan H, Liu KL, Wendel T, Murrill CS, (2011) Continuing HIV risk in New York City injection drug users: the association of syringe source and syringe sharing. Subst Use Misuse 46: 192-200.
25. Wood E, Kerr T, Marshall BD, Li K, Zhang R, et al. (2009) Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study. BMJ 338: b1649.
26. Smit C, Hallett TB, Lange J, Garnett G, de Wolf F, (2008) Late entry to HIV care limits the impact of anti-retroviral therapy in The Netherlands. PLoS One 3: e1949.
27. New York City Department of Health and Mental Hygiene BoHAPaC, editor (2010) Pediatric HIV/AIDS Surveillance Update New York City. New York HIV Epidemiology and Field Services Program, Pediatric Unit.
28. Hall HI, Espinoza L, Benbow N, Hu YW, (2010) Epidemiology of HIV infection in large urban areas in the United States. PLoS One 5: e12756.
29. (2010) Vital signs: HIV testing and diagnosis among adults-United States, 2001-2009. MMWR Morb Mortal Wkly Rep 59: 1550-1555.
30. CDC Fact Sheet: HIV among Hispanics/Latinos. US Department of Health and Human Services. Centers of Disease Control and Prevention.
31. Hu Yunyin WKT, Sheng Zhijuan, Kuo Chun-Mai, Frye Douglas M, (2010) Predictors for high HIV viral load (VL) among persons with HIV in Los Angeles County using laboratory surveillance and the HIV/AIDS Reporting System (HARS). American Public Health Associaton conference Denver, CO APHA.
32. (2010) HIV Epidemiology and Field Services Program Seminannual Report 5:2, October 2010 New York City NYC Department of Health and Mental Hygiene.
33. Christopoulos KA, Das M, Colfax GN, (2011) Linkage and retention in HIV care among men who have sex with men in the United States. Clin Infect Dis 52 (Suppl 2): S214-222.
34. New York City Department of Health and Mental Hygiene BoVS, editor (2007) Summary of Vital Statistics 2007.
35. (2010) Press Release 029-10: Health department announces that Bronx residents have received more than 375,000 HIV tests since 2008, surpassing a three-year goal in less than two, June 25, 2010.: NYC Department of Health and Mental Hygiene.
36. Foster C, Judd A, Tookey P, et al. (2009) Young people in the United Kingdom and Ireland with perinatally acquired HIV: the pediatric legacy for adult services. AIDS Patient Care STDs 23: 159-167.
37. Koening LJ, Nesheim S, Abramowitz S, (2011) Adolescents with perinatally acquired HIV: emerging behavioral and health needs for long-term survivors. Current Opinion in Obstetrics and Gynecology 23: 321-7.
38. Marhefka SL, Valentin CR, Pinto RM, Demetriou N, Wiznia A, et al. "I feel like I'm carrying a weapon." Information and motivations related to sexual risk among girls with perinatally acquired HIV. AIDS Care pp. 1-8.
39. Koenig LJ, Pals SL, Chandwani S, Hodge K, Abramowitz S, et al. Sexual transmission risk behavior of adolescents With HIV acquired perinatally or through risky behaviors. J Acquir Immune Defic Syndr 55: 380-390.
40. Diamond C, Buskin S, (2000) Continued risky behavior in HIV-infected youth. Am J Public Health 90: 115-118.
41. Berk ML, Schur CL, Dunbar JL, Bozzette S, Shapiro M, (2003) Short report: Migration among persons living with HIV. Soc Sci Med 57: 1091-1097.
42. Terzian AS, Holman S, Nathwani N, Robison E, Weber K, et al. (2009) Factors associated with preclinical disability and frailty among HIV-infected and HIV-uninfected women in the era of cART. J Womens Health (Larchmt) 18: 1965-1974.
43. Chadwick EG, Yogev R, Alvero CG, Hughes MD, Hazra R, et al. Long-term outcomes for HIV-infected infants less than 6 months of age at initiation of lopinavir/ritonavir combination antiretroviral therapy. AIDS 25: 643-649.
44. Morris M, Kurth AE, Hamilton DT, Moody J, Wakefield S, (2009) Concurrent partnerships and HIV prevalence disparities by race: linking science and public health practice. Am J Public Health 99: 1023-1031.
45. Millett GA, Flores SA, Peterson JL, Bakeman R, (2007) Explaining disparities in HIV infection among black and white men who have sex with men: a meta-analysis of HIV risk behaviors. AIDS 21: 2083-2091.
46. Porco TC, Martin JN, Page-Shafer KA, Cheng A, Charlebois E, et al. (2004) Decline in HIV infectivity following the introduction of highly active antiretroviral therapy. AIDS 18: 81-88.
47. Validiserri R, (2011) San Francisco's new approach to HIV prevention.: US Department of Health and Human Services.